HT-1080
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats HT-1080 as ChEMBL target CHEMBL614580. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why HT-1080 matters
HT-1080 is reviewed as HT-1080; the current evidence base includes 43 approved drugs, 3024 compounds, and 994 assays, with lead potency reaching pChEMBL 10.1.
HT-1080
Review this target as HT-1080.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 43 approved drugs, 3024 compounds, and 994 assays for this target. The dominant activity type is IC50. CHEMBL5082180 is the current potency anchor at pChEMBL 10.1.
Use CHEMBL5082180 as the tractability anchor when discussing potency (pChEMBL 10.1).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why HT-1080 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5082180
|
10.1 | IC50 | — |
|
|
No preferred name
CHEMBL553025
|
10.0 | IC50 | Approved |
|
|
No preferred name
CHEMBL159
|
10.0 | IC50 | Approved |
|
|
No preferred name
CHEMBL96926
|
9.9 | IC50 | — |
|
|
No preferred name
CHEMBL56157
|
9.8 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
IVOSIDENIB
CHEMBL3989958
|
2018 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
TEMSIROLIMUS
CHEMBL1201182
|
2007 |
|
|
VORINOSTAT
CHEMBL98
|
2006 |
|
|
TOPOTECAN
CHEMBL84
|
1996 |
|
|
GEMCITABINE
CHEMBL888
|
1996 |
|
|
DOCETAXEL
CHEMBL3545252
|
1995 |
|
|
DOCETAXEL ANHYDROUS
CHEMBL92
|
1995 |
|
|
VINORELBINE
CHEMBL553025
|
1994 |
|
|
PACLITAXEL
CHEMBL428647
|
1992 |
|
|
MITOXANTRONE
CHEMBL58
|
1987 |
|
|
ETOPOSIDE
CHEMBL44657
|
1983 |
|
|
MITOMYCIN
CHEMBL105
|
1981 |
|
|
DOXORUBICIN
CHEMBL53463
|
1974 |
|
|
DOXORUBICIN HYDROCHLORIDE
CHEMBL359744
|
1974 |
|
|
FLOXURIDINE
CHEMBL917
|
1970 |
|
|
CYTARABINE
CHEMBL803
|
1969 |
|
|
VINBLASTINE
CHEMBL159
|
1965 |
|
|
VINCRISTINE
CHEMBL90555
|
1963 |
|
|
COLCHICINE
CHEMBL107
|
1961 |
|
|
PROMETHAZINE
CHEMBL643
|
1951 |